nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Methaemoglobinaemia—Riluzole—amyotrophic lateral sclerosis	0.061	0.0817	CcSEcCtD
Metoclopramide—Stridor—Riluzole—amyotrophic lateral sclerosis	0.055	0.0737	CcSEcCtD
Metoclopramide—Trismus—Riluzole—amyotrophic lateral sclerosis	0.0537	0.0719	CcSEcCtD
Metoclopramide—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0371	0.0497	CcSEcCtD
Metoclopramide—HTR3A—cranial nerve—amyotrophic lateral sclerosis	0.0364	0.201	CbGeAlD
Metoclopramide—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.0305	0.0408	CcSEcCtD
Metoclopramide—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0274	0.0366	CcSEcCtD
Metoclopramide—Mania—Riluzole—amyotrophic lateral sclerosis	0.0247	0.033	CcSEcCtD
Metoclopramide—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.0238	0.0319	CcSEcCtD
Metoclopramide—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0234	0.0313	CcSEcCtD
Metoclopramide—Delirium—Riluzole—amyotrophic lateral sclerosis	0.0209	0.0279	CcSEcCtD
Metoclopramide—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.0204	0.0273	CcSEcCtD
Metoclopramide—HTR3A—nerve—amyotrophic lateral sclerosis	0.0187	0.103	CbGeAlD
Metoclopramide—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.0183	0.0244	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0179	0.024	CcSEcCtD
Metoclopramide—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.0173	0.0232	CcSEcCtD
Metoclopramide—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.017	0.0228	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0192	CcSEcCtD
Metoclopramide—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0184	CcSEcCtD
Metoclopramide—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.0124	0.0166	CcSEcCtD
Metoclopramide—HTR4—brain—amyotrophic lateral sclerosis	0.0119	0.0655	CbGeAlD
Metoclopramide—DRD2—nerve—amyotrophic lateral sclerosis	0.0114	0.0629	CbGeAlD
Metoclopramide—Asthma—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0151	CcSEcCtD
Metoclopramide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0141	CcSEcCtD
Metoclopramide—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0139	CcSEcCtD
Metoclopramide—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0139	CcSEcCtD
Metoclopramide—Depression—Riluzole—amyotrophic lateral sclerosis	0.01	0.0134	CcSEcCtD
Metoclopramide—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00978	0.0131	CcSEcCtD
Metoclopramide—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00936	0.0125	CcSEcCtD
Metoclopramide—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00917	0.0123	CcSEcCtD
Metoclopramide—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00896	0.012	CcSEcCtD
Metoclopramide—DRD2—hindbrain—amyotrophic lateral sclerosis	0.00855	0.0471	CbGeAlD
Metoclopramide—HTR3A—brainstem—amyotrophic lateral sclerosis	0.00801	0.0442	CbGeAlD
Metoclopramide—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00761	0.0102	CcSEcCtD
Metoclopramide—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00754	0.0101	CcSEcCtD
Metoclopramide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00735	0.00983	CcSEcCtD
Metoclopramide—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00721	0.00964	CcSEcCtD
Metoclopramide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00716	0.00959	CcSEcCtD
Metoclopramide—CYP17A1—medulla oblongata—amyotrophic lateral sclerosis	0.00712	0.0392	CbGeAlD
Metoclopramide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00702	0.00939	CcSEcCtD
Metoclopramide—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00693	0.00927	CcSEcCtD
Metoclopramide—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00679	0.00909	CcSEcCtD
Metoclopramide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00677	0.00906	CcSEcCtD
Metoclopramide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00665	0.0089	CcSEcCtD
Metoclopramide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00645	0.00864	CcSEcCtD
Metoclopramide—Oedema—Riluzole—amyotrophic lateral sclerosis	0.0064	0.00857	CcSEcCtD
Metoclopramide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00625	0.00836	CcSEcCtD
Metoclopramide—DRD3—nervous system—amyotrophic lateral sclerosis	0.00607	0.0335	CbGeAlD
Metoclopramide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00598	0.008	CcSEcCtD
Metoclopramide—DRD3—central nervous system—amyotrophic lateral sclerosis	0.00584	0.0322	CbGeAlD
Metoclopramide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00579	0.00775	CcSEcCtD
Metoclopramide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.0057	0.00764	CcSEcCtD
Metoclopramide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00569	0.00761	CcSEcCtD
Metoclopramide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00552	0.00738	CcSEcCtD
Metoclopramide—CYP17A1—nervous system—amyotrophic lateral sclerosis	0.00535	0.0295	CbGeAlD
Metoclopramide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00527	0.00706	CcSEcCtD
Metoclopramide—HTR4—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—amyotrophic lateral sclerosis	0.00525	0.0734	CbGpPWpGaD
Metoclopramide—CYP17A1—central nervous system—amyotrophic lateral sclerosis	0.00515	0.0284	CbGeAlD
Metoclopramide—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00514	0.0283	CbGeAlD
Metoclopramide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00508	0.0068	CcSEcCtD
Metoclopramide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00506	0.00677	CcSEcCtD
Metoclopramide—DRD2—brainstem—amyotrophic lateral sclerosis	0.0049	0.027	CbGeAlD
Metoclopramide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00471	0.00631	CcSEcCtD
Metoclopramide—DRD3—brain—amyotrophic lateral sclerosis	0.00464	0.0256	CbGeAlD
Metoclopramide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00459	0.00615	CcSEcCtD
Metoclopramide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00438	0.00586	CcSEcCtD
Metoclopramide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00423	0.00566	CcSEcCtD
Metoclopramide—HTR3A—nervous system—amyotrophic lateral sclerosis	0.0042	0.0231	CbGeAlD
Metoclopramide—CYP17A1—brain—amyotrophic lateral sclerosis	0.00409	0.0225	CbGeAlD
Metoclopramide—HTR3A—central nervous system—amyotrophic lateral sclerosis	0.00404	0.0223	CbGeAlD
Metoclopramide—Rash—Riluzole—amyotrophic lateral sclerosis	0.00403	0.0054	CcSEcCtD
Metoclopramide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00403	0.0054	CcSEcCtD
Metoclopramide—Headache—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00537	CcSEcCtD
Metoclopramide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.0038	0.00509	CcSEcCtD
Metoclopramide—HTR3A—brain—amyotrophic lateral sclerosis	0.00321	0.0177	CbGeAlD
Metoclopramide—CHRM1—nervous system—amyotrophic lateral sclerosis	0.00319	0.0176	CbGeAlD
Metoclopramide—CHRM1—central nervous system—amyotrophic lateral sclerosis	0.00307	0.0169	CbGeAlD
Metoclopramide—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00294	0.0162	CbGeAlD
Metoclopramide—DRD2—nervous system—amyotrophic lateral sclerosis	0.00257	0.0142	CbGeAlD
Metoclopramide—DRD2—central nervous system—amyotrophic lateral sclerosis	0.00247	0.0136	CbGeAlD
Metoclopramide—CHRM1—brain—amyotrophic lateral sclerosis	0.00244	0.0134	CbGeAlD
Metoclopramide—DRD2—cerebellum—amyotrophic lateral sclerosis	0.00242	0.0133	CbGeAlD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—ECE1—amyotrophic lateral sclerosis	0.00231	0.0323	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—CASP12—amyotrophic lateral sclerosis	0.00231	0.0323	CbGpPWpGaD
Metoclopramide—DRD2—brain—amyotrophic lateral sclerosis	0.00196	0.0108	CbGeAlD
Metoclopramide—HTR3A—Ion channel transport—TRPM7—amyotrophic lateral sclerosis	0.00196	0.0274	CbGpPWpGaD
Metoclopramide—DRD2—Hypothetical Network for Drug Addiction—GRIA2—amyotrophic lateral sclerosis	0.00183	0.0255	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00172	0.024	CbGpPWpGaD
Metoclopramide—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00154	0.0085	CbGeAlD
Metoclopramide—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00149	0.00819	CbGeAlD
Metoclopramide—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.00147	0.0205	CbGpPWpGaD
Metoclopramide—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00145	0.008	CbGeAlD
Metoclopramide—DRD3—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00143	0.02	CbGpPWpGaD
Metoclopramide—CYP11B2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00126	0.0176	CbGpPWpGaD
Metoclopramide—CYP2D6—brain—amyotrophic lateral sclerosis	0.00118	0.0065	CbGeAlD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00111	0.0155	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00111	0.0155	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00111	0.0155	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.0011	0.0153	CbGpPWpGaD
Metoclopramide—CYP11B1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00108	0.0151	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00107	0.015	CbGpPWpGaD
Metoclopramide—CYP17A1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00101	0.0142	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000967	0.0135	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—CASP9—amyotrophic lateral sclerosis	0.000913	0.0128	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000885	0.0124	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000866	0.0121	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000834	0.0117	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000822	0.0115	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00078	0.0109	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000773	0.0108	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000762	0.0107	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000713	0.00997	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000709	0.00991	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000682	0.00954	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000666	0.00931	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000663	0.00927	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00066	0.00922	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000623	0.00871	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000573	0.00801	CbGpPWpGaD
Metoclopramide—CYP11B2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000562	0.00786	CbGpPWpGaD
Metoclopramide—CYP11B2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000554	0.00775	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00053	0.00741	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—PFN1—amyotrophic lateral sclerosis	0.000489	0.00683	CbGpPWpGaD
Metoclopramide—CYP11B1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000484	0.00677	CbGpPWpGaD
Metoclopramide—CYP11B1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000478	0.00668	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000457	0.00638	CbGpPWpGaD
Metoclopramide—CYP17A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000453	0.00633	CbGpPWpGaD
Metoclopramide—CYP17A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000447	0.00625	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00044	0.00615	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000431	0.00602	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000431	0.00602	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000427	0.00597	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000402	0.00561	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000398	0.00556	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000394	0.00551	CbGpPWpGaD
Metoclopramide—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000385	0.00538	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—CASP3—amyotrophic lateral sclerosis	0.000384	0.00537	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000381	0.00532	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000378	0.00529	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000374	0.00523	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000374	0.00523	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000373	0.00521	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000371	0.00519	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000371	0.00519	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000366	0.00512	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000347	0.00485	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000347	0.00485	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000346	0.00484	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000344	0.00481	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00034	0.00475	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000339	0.00473	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000333	0.00466	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000324	0.00453	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000318	0.00444	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000316	0.00442	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000316	0.00441	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—DAO—amyotrophic lateral sclerosis	0.000311	0.00435	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000305	0.00426	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000297	0.00415	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000295	0.00413	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000291	0.00407	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000288	0.00403	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000286	0.004	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000285	0.00398	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000278	0.00388	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000274	0.00383	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000268	0.00375	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000264	0.00369	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000251	0.00351	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000248	0.00347	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000243	0.00339	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000242	0.00338	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000241	0.00337	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000237	0.00331	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000236	0.0033	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000235	0.00329	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000228	0.00318	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000218	0.00304	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000203	0.00284	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000202	0.00283	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.0002	0.0028	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000198	0.00277	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00019	0.00266	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000188	0.00262	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000184	0.00258	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00018	0.00252	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000179	0.0025	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000176	0.00245	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000174	0.00243	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000171	0.00239	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000167	0.00234	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000163	0.00228	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000163	0.00228	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.00016	0.00224	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000154	0.00215	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000148	0.00207	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000144	0.00202	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000141	0.00197	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000138	0.00193	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000137	0.00192	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000136	0.0019	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000133	0.00186	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000132	0.00184	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000129	0.0018	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000124	0.00173	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000123	0.00172	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000123	0.00171	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000121	0.00169	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000112	0.00156	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000106	0.00148	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000105	0.00147	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000105	0.00147	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000104	0.00146	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000103	0.00145	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000102	0.00143	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.88e-05	0.00138	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.64e-05	0.00135	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.64e-05	0.00135	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.61e-05	0.00134	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	9.46e-05	0.00132	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	9.39e-05	0.00131	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	9.39e-05	0.00131	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	9.26e-05	0.00129	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	9.06e-05	0.00127	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.01e-05	0.00126	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.83e-05	0.00123	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.73e-05	0.00122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.59e-05	0.0012	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	8.59e-05	0.0012	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	8.32e-05	0.00116	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.28e-05	0.00116	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.13e-05	0.00114	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	8.05e-05	0.00112	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.98e-05	0.00112	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	7.88e-05	0.0011	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.75e-05	0.00108	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.61e-05	0.00106	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	7.51e-05	0.00105	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	7.47e-05	0.00104	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.39e-05	0.00103	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.38e-05	0.00103	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.3e-05	0.00102	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—APOE—amyotrophic lateral sclerosis	7.27e-05	0.00102	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.22e-05	0.00101	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.12e-05	0.000995	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.93e-05	0.000969	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	6.79e-05	0.000949	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.79e-05	0.000949	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.72e-05	0.000939	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.57e-05	0.000919	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.43e-05	0.000899	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.37e-05	0.00089	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—APOE—amyotrophic lateral sclerosis	6.26e-05	0.000876	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.23e-05	0.000871	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	6.11e-05	0.000854	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.94e-05	0.000831	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—APOE—amyotrophic lateral sclerosis	5.86e-05	0.000819	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	5.72e-05	0.000799	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.65e-05	0.00079	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	5.6e-05	0.000782	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.59e-05	0.000781	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.53e-05	0.000773	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.47e-05	0.000765	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.4e-05	0.000754	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.17e-05	0.000723	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.14e-05	0.000719	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.02e-05	0.000702	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.98e-05	0.000696	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.89e-05	0.000683	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	4.75e-05	0.000664	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.71e-05	0.000658	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.67e-05	0.000653	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.57e-05	0.000639	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.55e-05	0.000636	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.48e-05	0.000627	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.45e-05	0.000622	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.39e-05	0.000613	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.29e-05	0.0006	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.13e-05	0.000577	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.04e-05	0.000565	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.01e-05	0.000561	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	3.9e-05	0.000545	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.84e-05	0.000537	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.84e-05	0.000536	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.76e-05	0.000525	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.61e-05	0.000504	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.6e-05	0.000503	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.52e-05	0.000493	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.43e-05	0.00048	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.36e-05	0.000469	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.31e-05	0.000463	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.19e-05	0.000446	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.97e-05	0.000415	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.94e-05	0.00041	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.87e-05	0.000402	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.76e-05	0.000386	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.7e-05	0.000378	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.45e-05	0.000343	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.44e-05	0.000341	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.39e-05	0.000334	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.27e-05	0.000317	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.22e-05	0.000311	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.1e-05	0.000293	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.93e-05	0.000269	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.89e-05	0.000264	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.88e-05	0.000262	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.84e-05	0.000257	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.78e-05	0.000249	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.6e-05	0.000224	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.58e-05	0.000221	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.44e-05	0.000202	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.41e-05	0.000198	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.37e-05	0.000191	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.34e-05	0.000187	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.23e-05	0.000171	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.21e-05	0.000169	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.2e-05	0.000168	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.09e-05	0.000152	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.26e-06	0.000129	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.07e-06	0.000127	CbGpPWpGaD
